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Breakthrough pain in cancer patients
ABSTRACT
Breakthrough pain is a brief episode of severe pain occurring in patients undergoing analgesic procedures in the 
course of cancer. It affects about 70% of patients and significantly influences their quality of life. It is important 
to identify specific types of pain and inducing factors. Treatment is based on modification of pain management 
including use of immediate-release drug formulations.
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Introduction
Pain is one of the most common clinical symptoms 
associated with malignant diseases. Although it can 
occur at every stage of cancer, 30–40% of patients suf-
fer from pain at diagnosis [1]. Among actively treated 
patients the percentage is even higher and accounts for 
50%, and in advanced disease it is found in up to 90% 
patients [2]. Despite intensive treatment of pain, some 
patients experience short-term exacerbation of pain of 
very high intensity, known as breakthrough pain. 
In this publication the pathogenesis, diagnosis, and 
treatment of breakthrough pain are presented based on 
a review of currently available literature data. 
The causes and evaluation of pain 
related to cancer
According to the definition by the International 
Association for the Study of Pain (IASP), pain is an 
unpleasant feeling and emotional experience related to 
preexisting or potential injury of the tissues. It is believed 
that pain contains physical, psychosocial, emotional, and 
spiritual components. However, this is always a subjec-
tive sensation. The pathogenesis of pain in cancer is 
very complex. It could result from infiltration of tissues 
(40–90% of patients), asthaenia and cancer cachexia 
(10–30% of patients), or it can be a consequence of 
active anticancer treatment (10–20% of patients), but 
in some patients the real cause remains unknown [3, 4].
Intensity of pain should be assessed at every visit, 
and in order to do this there are different scales based 
on a variety of criteria. The most commonly used is the 
numerical rating score (NRS) with the level of pain 
intensity assessed from 0 to 10 — 0 represents a lack 
of pain (“no pain”) and 10 reflects the most extreme 
pain (“the strongest pain you can imagine”). The 
visual analogue score (VAS) is also frequently used; 
patient describes pain intensity on a numerical scale of 
100 mm length (0 — no pain, 100 — the strongest pain 
imaginable). The descriptive Likert scale (“no pain”, 
“mild pain”, “moderate pain”, “strong pain”, “severe 
pain”) is the least accurate, but it is often the easiest to 
understand by the patient.
Breakthrough pain
Cancer can be accompanied by baseline as well 
as breakthrough pain. Baseline pain is consistent and 
long-lasting (most commonly 12 hours or longer), and is 
usually controlled by long-term drug administration. It 
can have somatic, visceral, or neuropathic background. 
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The treatment should be conducted according to the 
guidelines developed by the World Health Organization 
(WHO). The WHO analgesic ladder allows sufficiently 
controlling pain in 70–90% of patients [5].
Despite good control of baseline pain some patients 
experience short-term, transient episodes of strong pain. 
This is called breakthrough pain and has been described 
in literature for the last 25 years [6]. No single, valid defi-
nition of breakthrough pain has been established to date. 
A large, multicentre clinical trial involving 1095 patients 
treated in 24 countries confirmed that the incidence of 
breakthrough pain as well as treatment methods were 
significantly determined by the breakthrough pain defi-
nition adopted by investigators [7]. 
Breakthrough pain is most frequently defined as 
transient, exacerbating pain, which appears during 
baseline cancer pain, and is sufficiently controlled with 
long-acting opioid drugs. It was estimated that break-
through pain affects 40–80% of cancer patients [8]. The 
incidence is different depending on cancer stage, and 
similarly to baseline pain it increases along with advance-
ment of disease. Among patients with advanced disease, 
breakthrough pain concerns nearly 90% of cases [8]. 
Breakthrough pain is characterised by rapid onset, 
usually developing within a few minutes or even seconds 
(approximately three minutes on average), is stronger 
than baseline pain, and can reach 7 points on a 10-point 
scale, and moreover lasts for a very short time (30 min-
utes on average). The number of breakthrough pain 
episodes varies; usually there are a few during a day 
(Figure 1) [1]. 
In the majority of cases there are no prodromal 
symptoms of breakthrough pain.
Breakthrough pain could have either receptor (so-
matic or visceral) or neuropathic pathogenesis. Receptor 
pain accounts for approximately 30–40% of cases; it 
results from irritation of neural ends by tissue damaging 
factors, and is transmitted as an impulse to the central 
nervous system (CNS). Neuropathic pain in 25–35% of 
cases results from irritation or injury of nervous system 
structures (nerves, roots, spinal cord). In some patients 
(approximately 20%) breakthrough pain has a mixed 
nature [9, 10]. Usually the mechanism and location of 
breakthrough pain are the same those of baseline pain.
Breakthrough pain can be either predictable, e.g. 
induced by particular stimulus (position changes, touch, 
cough, breathing, therapeutic factors, care procedures), 
or is difficult to anticipate [6]. The relation with circa-
dian rhythm was observed; breakthrough pain is more 
frequent during the day (10:00 AM–06:00 PM — 60% of 
patients) [11]. In the majority of cases (70–80%) cancer 
is the direct cause of breakthrough pain, less frequently 
it is due to an anticancer treatment (10–20%), and in less 
than 10% of patients breakthrough pain is not connected 
with any of the mentioned factors [9].
Breakthrough pain should be differentiated from 
so-called “end-of-dose pain”, which is observed within 
the last hours of action of extended release opioid 
drugs. The intensity of “end-of-dose pain” increases 
slowly and indicates a time correlation with the used 
treatment. 
Diagnostics
Assessment of pain is an essential part of physical 
examination of cancer patients. Taking into considera-
tion the high percentage of patients with concomitantly 
occurring breakthrough pain, the additional questions 
have a special value, giving a more comprehensive clini-
cal picture. Table 1 presents some questions prepared 
based on one of the questionnaires available in the 
literature, which assess breakthrough pain (Alberta 
Breakthrough Pain Assessment, ABPAT) [8]. Another 
questionnaire has also been published, validated in 
patients with different solid tumours (BAT, Break-
through Pain Assessment Tool) [12]. Nevertheless, 
the tools for diagnostics and assessment of treatment 
efficacy need additional evaluation in future prospec-
tive clinical trials.
Figure 1. Characteristics of breakthrough pain
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Table 1. Questionnaire for assessment of breakthrough pain (based on [8])
1. How was the intensity of baseline pain during last days?
2. What analgesic drugs are taken permanently? What are the doses of drugs?
3. Is pain control satisfactory during the majority of the day?
4. Do episodes of rapidly increasing pain occur?
5. What is the average intensity of those additional pain episodes?
6. How many episodes do occur per day/week?
7. How quickly do the symptoms increase and how long do they last?
8. Are their features the same as the characteristics of baseline pain?
9. Do they appear either spontaneously or related to any factor?
10. Do they appear regularly before taking baseline analgesic drugs?
11. How do they affect daily life?
12. Do any drugs that are taken relieve the additional, severe pain? Are any other methods efficacious?
13. What are those drugs and in what doses are they taken?
Clinical implications
Similarly to baseline pain, breakthrough pain sig-
nificantly affects patient’s quality of life (QoL) [13, 14].
Davies at al. published the results of a multicentre 
clinical trial involving 1000 patients treated in 28 spe-
cialised palliative care units between 2008 and 2011 in 
13 European countries [13]. The patients were classified 
as eligible to participate in the trial based on a question-
naire of five questions. In 44% of patients breakthrough 
pain was induced by particular factors, in 41.5% it was 
an idiopathic symptom, and in 14.5% the aetiology was 
mixed. It was revealed that mobility problems and dif-
ficulties with basic daily activities were more frequent 
among patients with breakthrough pain induced by 
specific factors, whereas patients with idiopathic pain 
more commonly reported changes of mood and sleep 
problems (Tab. 2) [13].
Portenoy et al. assessed the influence of breakthrough 
pain on QoL using the Beck Depression Inventory 
(BDI) questionnaire, the Beck Anxiety Inventory (BAI) 
questionnaire, and by measurement of baseline pain 
intensity based on the VAS scale. Among 178 patients 
with well-controlled baseline pain two groups of patients 
were extracted and evaluated, depending on whether 
Table 2. Influence of breakthrough pain on quality of life [13]
All patients Patients with specific 
factor
Patients with 
idiopathic pain
p
General activity 7 7 7 0.124
Mood 7 6 7 0.016
Mobility 7 8 6 < 0.001
Work 8 9 8 0.001
Interpersonal relations 5 5 5 0.297
Sleep 5 5 6 < 0.001
Life satisfaction 7 7 7 0.995
or not they had breakthrough pain. In 65% of patients 
breakthrough pain resulted from cancer, and in the re-
maining cases it was connected with the treatment used. 
In patients with breakthrough pain the baseline pain was 
more intense (34.2 vs. 16.7 in VAS scale — p < 0.01). 
Moreover, it was assessed how the pain influenced mood, 
work, sleep, mobility, social relations, and life satisfaction. 
Every aspect was evaluated on a numerical scale from 0 to 
10 (0 — no influence, 10 — entire influence). In cases of 
BDI and BAI scales the patients responded to 21 ques-
tions, graded from 0 to 3 (0 represents no symptoms and 
3 the highest intensity of symptoms) (Tab. 3) [14].
Of note, breakthrough pain could negatively affect 
prognosis [15], and also adversely influence duration of 
cancer treatment [16]. Precise diagnosis of the type of 
pain and early introduction of appropriate treatment 
should be sought.
Management
The management of breakthrough pain is primarily 
based on pharmacological treatment, but in some cases 
it is also possible to use surgical procedures (blockades, 
neurolysis, TENS) or aetiotropic treatment (e.g. pallia-
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Table 3. The influence of breakthrough pain on quality of life [14]
Patients without BP Patients with BP p
Activity 2.7 4.0 < 0.001
Mood 2.5 3.6 < 0.001
Mobility 2.3 3.5 < 0.001
Work 2.5 3.9 < 0.001
Social relations 1.9 2.9 < 0.001
Sleep 2.2 3.2 < 0.001
Life satisfaction 2.7 3.7 < 0.001
Cumulatively 16.7 24.8 < 0.001
BDI 12.8 18.2 < 0.001
BAI 9.9 17.9 < 0.001
BP — breakthrough pain; BDI — Beck Depression Inventory; BAI — Beck Anxiety Inventory
tive irradiation of bone lesions, use of bisphosphonates). 
It is also essential to identify and prevent the action of 
the factors inducing breakthrough pain (e.g. excessive 
physical effort, persistent cough, constipation). Before 
making a therapeutic decision, the level of baseline 
pain control should be assessed; in cases of more than 
four episodes of breakthrough pain per day increasing 
the dose of permanently administered analgesic drugs 
could be justified [17].
Simple analgesics (effervescent tablets of paraceta-
mol or metamizole) could be effective in pharmaco-
therapy of breakthrough pain [18]; however, patients 
who continue to take opioid drugs of modified release 
most commonly demand introduction of opioids. The 
choice of treatment should be based on both the type 
of breakthrough pain (incidental, idiopathic) as well as 
the type of the drug previously used for treatment of 
baseline pain [17]. 
Taking into consideration the dynamics of break-
through pain, its rapid increase, and short duration, it 
seems to be optimal to use drugs of immediate release, 
demonstrating an analgesic effect within a few minutes after 
administration and maintaining their action for a moder-
ately long time, to minimise the adverse effects of therapy. 
For a long time, orally administered morphine in 
immediately released formulations was the drug of 
choice in the treatment of breakthrough pain (the rec-
ommended dose is 10–15% of daily dose of baseline 
opioid); however, the pharmacokinetic features of oral 
morphine are not optimal. After oral administration of 
hydrophilic opioids (morphine, oxycodone) maximum 
serum concentration is reached within 30–80 minutes 
(the drug is absorbed only in the proximal part of the 
small intestine) [19]. Analgesic effect appears ap-
proximately 30 minutes after drug administration, which 
makes those drugs inappropriate in the treatment of 
breakthrough pain. An exceptional case is incidental 
breakthrough pain that can be predicted by the patient. 
In this situation it is reasonable to take an opioid drug 
dose of immediate release 30–45 minutes before the 
activity that could cause the pain [19].
The pharmacotherapy of idiopathic breakthrough 
pain comprises some challenges because this pain is dif-
ficult to predict and lasts for a relatively short time, but 
its intensity is high and increases within minutes. Thus, 
the activity of an optimal drug should be characterised 
by similar dynamics, with concomitant acceptable safety 
profile. The efficacy of a few formulations of fentanyl 
(a lipophilic drug, penetrating well through mouth mucosa 
and easily crossing the blood-brain barrier) in the treat-
ment of breakthrough pain in patients continuously taking 
the opioid drugs was assessed in randomised clinical trials 
[20]. Pharmacokinetic features of fentanyl allow quick 
absorption of the drug into the circulation and faster an-
algesic effect. There are different formulations of fentanyl 
available: buccal tablets, lollipops, and intranasal aerosol.
The widely evaluated formulation is oral transmu-
cosal citrate fentanyl (OTCF), applied in the form of 
“lollipops” (unavailable in Poland). Its efficacy was 
compared with placebo as well as morphine in formula-
tions of immediate release [20–22]. It was shown that 
fentanyl with this route of administration significantly 
decreases the symptoms in approximately 75% of pa-
tients, the analgesic effect is faster than after morphine 
(approximately 10 minutes), and the treatment is in 
general quite well tolerated; the most common adverse 
events include nausea, dizziness, and constipation. 
Some inconvenience was reported by patients because 
of necessity to maintain an applicator with the drug in 
the mouth until the lozenge is entirely dissolved. For 
some patients the bitter taste of the drug and its form 
of application were the disadvantages of such therapy.
An alternative is tablet form, which, after placing in 
the posterior part of mouth between gum and cheek, 
releases the dose of the drug (100, 200, 400, 600, or 
800 μg of fentanyl). Approximately 55% of the dose is 
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Table 4. Response rates after administration of varied formulations of fentanyl in different time periods
Compared drugs RR (%) 
10 min.
RR (%) 
15 min.
RR (%) 
30 min.
Mercadante 2009 [25] INF vs. OTFC 50 vs. 20 70 vs. 40 90 vs. 80
Kress 2009 [24] INF vs. placebo 58 ND 80
Portenoy 2006 [22] FBT vs. placebo ND 13 48
Slatkin 2007 [29] FBT vs. placebo 16 30 51
RR — response rate; INF — intranasal fentanyl; OTFC — oral transmucosal citrate fentanyl; FBT — fentanyl buccal tablets; ND — no data
absorbed through mucous membrane and the dissolving 
of the lozenge takes just a few minutes (14–25 minutes 
on average). The efficacy of such a formulation was com-
pared to placebo. In patients treated with fentanyl the 
pain intensity was reduced by 3.2 points in an 11-point 
scale, compared to 1.8 points in the control group 
(p < 0.0001) [22]. Furthermore, patients treated with 
fentanyl statistically significantly more rarely demanded 
add-on analgesic drugs, and within 30 minutes after drug 
administration 24% of patients reported symptoms of 
relief by 50% (16% in the placebo group). The treatment 
was well tolerated. The most common adverse events 
included nausea, dizziness, and fatigue [22]. Ulceration 
in the area application was noted in 2% of patients in 
the experimental group. Relatively long time of drug 
absorption (15–25 minutes) and necessity of keeping 
the tablet under the cheek for the whole time could be 
perceived as inconvenient.
A very interesting form of fentanyl use in break-
through pain is intranasal aerosol. In 2009 this for-
mulation was approved in European Union (EU) 
countries. There are a few dosage forms (50, 100, and 
200 μg/dose), which makes it easier to set a proper dose 
for a particular patient. Titration should be started from 
the dose of 50 μg, and in case of lack of efficacy this dose 
could be repeated after 10 minutes. It is estimated that 
maximum serum concentration of fentanyl is reached 
approximately 13 minutes after application and the 
analgesic effect is observed after just seven minutes 
[23]. The safety and efficacy of such a form of fentanyl 
in the treatment of breakthrough pain were evaluated 
in several randomised clinical trials. 
In a group of 120 patients it showed significant 
benefit, which was measured by reduction of pain in-
tensity 10 minutes after drug application (decreasing 
by 2.36 points in the VAS scale compared to 1.1 points 
in the placebo group) [24]. Additionally, there were no 
major toxicities, and the most common adverse events 
included nausea and dizziness.
Intranasal fentanyl was also compared with trans-
mucosal formulations. In the group of 139 patients with 
breakthrough pain intranasal fentanyl was titrated and 
subsequently also OTFC was administrated in the same 
pattern [25]. The time until decreasing pain intensity and 
the percentage of patients who rated that response to the 
drug as “meaningful” were assessed. The results favoured 
the intranasal formulation [analgesic effect after 11 min-
utes as compared with 16 minutes for oral formulation, 
decreasing of pain intensity by 33% within 5 minutes after 
drug administration in 25% of patients comparing to 6.8% 
(p < 0.001) for oral formulation, easier application as well 
as better tolerance of treatment] (Tab. 4) [25].
Lesions of the mucous membrane, resulting from 
oncology treatment or underlying disease, are very 
important factor, that should be considered during 
choosing transmucosal fentanyl formulation for treat-
ment of breakthrough pain. One of these problems is 
a dry mouth, which could affect up to 80% of patients 
with advanced malignant disease [26]. It makes dissolv-
ing of buccal tablets very difficult, increases discomfort, 
and decreases the efficacy of the treatment. Another 
complication is concomitant presence of mucosal in-
flammation. The pharmacokinetics of the drug were 
assessed in patients with common cold as well as allergic 
rhinitis, demanding use of oxymetazoline [27, 28]. Whilst 
common cold did not change the pharmacokinetics, 
administration of oxymetazoline significantly prolonged 
the absorption time of fentanyl from the mucosa. How-
ever, it should be remembered that in cases of epistaxis 
or ulceration of nasal mucosa it is recommended that 
the treatment with intranasal formulation be stopped 
and another form of therapy introduced. 
A meta-analysis published by Zeppatella et al. 
showed that transmucosal fentanyl formulations allow 
better pain control in a shorter time period as compared 
to placebo or to oral morphine of immediate release [30].
ESMO recommendations regarding management of 
breakthrough pain indicate the necessity of appropriate 
treatment of baseline pain. Oral morphine formula-
tions of immediate release are recommended for the 
treatment of predictable episodes of breakthrough 
pain, when the drug could be taken at least 20 minutes 
before the action of the triggering factor. In other cases 
of breakthrough pain fentanyl is recommended in the 
form of buccal tablets or intranasal aerosol [31].
The recommendations of the Polish Society of Clini-
cal Oncology (PTOK, Polskie Towarzystwo Onkologii 
Klinicznej) reflect the ESMO guidelines [32]. Table 5 
presents the drugs recommended in the treatment of 
breakthrough pain. 
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Summary
Pain treatment is an integral part of management in 
patients with cancer. Despite active treatment, in some 
patients pain control remains unsatisfactory, which also 
applies to breakthrough pain. A lack of unambiguous 
definition as well as a validated tool for assessment 
of pain still significantly impedes the diagnostics and 
treatment of breakthrough pain. Management is based 
on modification of the treatment of baseline pain, 
considering opioid drugs of immediate release, used in 
1/6 of baseline drugs’ daily dose. Transmucosal opioids 
ensure faster analgesic effect than other oral formula-
tions, and intranasal aerosol seems to be currently the 
most beneficial route of administration.
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Table 5. Opioids used in the treatment of breakthrough pain [32]
Drug Posology Maximum dose
Fentanyl buccal tablets Individual dosage through titration starting from 100 or 200 µg 
per dose
800 µg per dose/per episode
Fentanyl intranasal 
spray
Individual dosage through titration starting from 50 µg per dose 
Do not exceed two doses, with interval between doses of at least 
10 minutes
Up to four episodes per day
Fentanyl sublingual 
tablets 
Individual dosage through titration starting from 100 µg per dose 800 µg per dose/per episode
Morphine tablets of 
immediate release
1/6 of daily dose of opioid drugs using in the treatment of 
baseline pain
Maximum dose not defined
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COMMENT ON THE PAPER
The incidence of breakthrough pain determines 
its’ importance in patients with malignant diseases. At 
least 30% of patients experience breakthrough pain 
during anticancer treatment, and in patients with 
advanced disease the incidence is as high as 70% [1]. 
Currently in Poland cancer is diagnosed in approxi-
mately 150,000 patients annually [2] — therefore, the 
problem of pain treatment is quite important, at least 
from an epidemiological point of view. Pain in can-
cer patients is associated with underlying disease as 
well as anticancer treatment, but also it could result 
from different concomitant medical conditions. The 
pathophysiology of pain differs, due to a variety of 
mechanisms and clinical features of nociceptive and 
neuropathic symptoms. Effective pain treatment re-
quires understanding of conditions mentioned above 
as well as an individualised approach, which should 
consider also the type of cancer.
Specific diagnostic and therapeutic challenges 
are connected with so-called breakthrough pain, 
which affects at least 50% of cancer patients [3]. It is 
characterised by periodic and usually short-term (ap-
proximately 30 minutes) exacerbation of pain in patients 
with baseline symptoms generally well controlled with 
opioids. The management should be based on the type 
and pathomechanism of breakthrough pain — it is 
recommended to use “salvage” opioids of rapid-onset 
and short-term activity [3]. Frequent episodes of break-
through pain should lead to analysis of the value of 
analgesic treatment compared to preexisiting symptoms, 
and they also have some relevance in classification of 
general intensity of pain [4]. 
Pain management should be an integral part of 
supportive care in oncology because effective analgesic 
treatment is very often one of the most important meas-
ures of quality of life in cancer patients. The complexity 
of breakthrough pain in cancer patients as well as its’ 
high frequency of this symptom justifies the need for the 
education of all physicians taking care of patients with 
malignant diseases. It should also be underlined that ef-
fective pain treatment demands the integrity of all thera-
peutic modalities, especially palliative radiotherapy. 
The effectiveness and side effects of pain management 
should be carefully monitored, considering the risk of 
adverse drug-drug interactions and other drugs used by 
patients. Well established interpersonal contact with 
the patient and family members is of high importance. 
References
1. Foley KM. Pain assessment and cancer pain syndromes. W: Doyle D, 
Hanks GWC, MacDonald N. Oxford Textbook of Palliative Medicine. 
Oxford University Press, Oxford 1997: 148–165.
2. Didkowska J, Wojciechowska U. Nowotwory złośliwe w Polsce w 2013 
roku. Centrum Onkologii — Instytut, Warszawa 2015.
3. Mercadante S, Marchetti P, Cuomo A et al. Breakthrough pain and its 
treatment: critical review and recommendations of IOPS (Italian On-
cologic Pain Survey) expert group. Support Care Cancer 2016; 4: 
961–968.
4. Leppert W, Majkowicz M. Adaptacja Karty Oceny Bólu Memorial (Me-
morial Pain Assessment Card) do warunków polskich — propozycja 
standardowego narzędzia służącego do oceny bólu i monitorowania 
leczenia bólu u chorych na nowotwory. Med Paliat 2011; 3: 207–213. 
Translation: dr n. med. Dariusz Stencel
